Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart disease) cause of death in the US in 1970. The National Cancer Institute (NCI) from its establishment had broad powers, including the creation […]

Doc Gumshoe's June 2023 Short Takes

Doc Gumshoe looks at diet, supplements and drugs

Aside from the tiny minority of people who can actually say what each of those initials stand for, we can divide the populace into two groups – those who specifically know that CRISPR is a tool used in gene editing and those who know (or figure) that it’s a highly promising but exceedingly complex technique […]

Thinking about COVID-19 almost gives me a migraine, or at least a heavy and achy sensation in my noggin – perhaps not an actual migraine, thankfully, but threatening and unpleasant all the same.   Happily, thinking about migraines will not give me COVID-19.   But migraines are by no means a topic of no consequence, […]

Mostly in these Doc Gumshoe pieces I try to keep my focus on what the physicians and researchers and pharmaceutical outfits are doing to try to treat, or at least manage, all these diseases, ailments, and conditions that affect our lives.   But other issues keep thrusting themselves into the picture, especially the cost factor. […]

What's teased as the latest Alzheimer's Disease recommendation from Dave Lashmet for Stansberry's Investment Advisory?

Doc Gumshoe on opioids, FDA approvals, and, yes the Wuhan Coronavirus

The answer to that foolish question is certainly going to be “both.” But the finger pointing at the guilty party has wobbled around a good deal in the past few years, and just before Christmas, the American Heart Association came out with a set of dietary recommendations once again apparently putting at least some blame […]

Doc Gumshoe explains CRISPR, CAR-T and more...

What's Green Chip Stocks promoting with “DAY ZERO: The Company That Will End Aging and Make You Rich.”

Part Two of Doc Gumshoe's look at Cancer in 2019

Checking out a Nova-X teaser, plus updates on Nokia, Facebook, Fairfax India and more...

Doc Gumshoe looks at the state of cancer treatment... and some of the interesting drug approvals from 2018

Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.”   I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]

Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me.   Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy?   But I probably pay more attention to […]

Oxford Income Letter teases: "One company with the key patent could see a $147 billion sales surge... And YOU could collect a retirement fortune if you act before November 9."

Hello, dear friends — I have a few portfolio updates to start with as I get you updated on a few trades that triggered since I last wrote, so adjustments to the portfolio (including a few buys and sells) will be the focus of today’s Friday File. The latest update to the Real Money Portfolio […]

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

Doc Gumshoe with news on antibiotics, prostate cancer, and migraines

What's being teased by Nilus Mattive's The Rich Life?

A few minor Real Money Portfolio trades, plus updates on Aptiv, Berkshire, Clean TeQ, CoreSite, eCobalt, Estre Ambiental, Facebook, Fairfax, JD.com, Kennedy-Wilson, Ligand, Match, Maverix, Medical Properties Trust, Qualcomm, Sandstorm, Shopify, Square, Skyworks, and Xylem... phew!

What drugs hit in 2017? How did approvals compare to 2016?

What's being teased by Exponential Tech Investor with that February 27 news coming and hinted-at 35,000% gains?

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He’s agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see his past articles and most recent comments here.] The death of Mr. Chiang, who was always kind, has never set well […]

What's Ernie Tremblay's CD19 AB4 Teaser All About?

Doc Gumshoe checks in on CAR-T, HRT, Prostate Cancer and more...

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

Doc Gumshoe closes out the year with looks at niacin, Co-Q10, carnosine, telomeres and more...

Based Upon an Original Screenplay Idea by Alan Harris

Doc Gumshoe finishes his series on Alzheimer's Disease

10/28 update: this article is about a week old, but the teaser ads have changed a bit — the newsletter is now also being pitched under the headline, “Has this Maine town bottled the fountain of youth?” and it’s now also going out under the name Dr. Richard Robinson, who apparently works on the newsletter […]

[ed note: Michael Jorrin, who I like to call “Doc Gumshoe,” writes non-investment articles for us about medical and health topics a couple times a month. He is a medical writer, not a doctor, and his words and thoughts are his own.] Just possibly a tiny few of the Gumshoe faithful may remember that advertising […]

What stocks are being teased by King for his Military-Tech Report?

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a medical writer (not a doctor) who shares his thoughts with our readers a couple times a month. He does not generally cover investing topics, but I find his discussions of broader health issues interesting and useful. Enjoy!] Doc Gumshoe would not be […]

PART TWO OF DOC GUMSHOE'S LOOK AT CANCER

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]

THE YEAR THAT WAS

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. His previous columns can be found here. Enjoy!] Every New Year, a friend and I flew to Boston. She’d gone to medical school […]

DR. KSS ON THREE NEW COMPANIES FOR POTENTIAL PROFIT FROM PAIN

Doc Gumshoe takes a look at "biologic generics"

Dr. KSS Looks at clotting for the Irregulars

[ed note: Michael Jorrin, a medical writer who we have dubbed “Doc Gumshoe” (he’s not a doctor), shares his thoughts with us once or twice a month — what follows is his latest missive, the words and opinions below are his alone.] I didn’t plan it this way, but the timing of this Doc Gumshoe […]

Second of Two Parts

[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]

Here's to a "Green" Biotechnology Company....In A Manner of Speaking

DR. KSS TAKES ON ANTIBIOTICS

[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]

As promised, we’re following up with the rest of the picks that Stephen Leeb (sorry, Dr. Stephen Leeb) is pitching as his “MCR” Plan. If you missed our first entry as we began demystifying this particular ad, you can see it here — the short version is, he’s touting dividend paying stocks in the medical […]

Here we have another email ad for the Skousen Hedge Fund Trader, which has steered us toward both good and bad ideas lately (at least, good or bad if we’re looking at short term performance — which isn’t necessarily what Skousen is aiming for). This one sounds pretty appealing when we have markets moving like […]

This one comes in from Stansberry and Associates, as an ad for Porter Stansberry’s Investment Advisory — if you subscribe, they’ll send you the special report: “Part D Compensation”— Monthly Checks for the Next 9 Years. Now, Stansberry and his folks love to come up with new terms and phrases to describe the investment strategies […]